Dr. Hassan Shora

Dr. Hassan Shora
Senior consultant physician & Head,Internal medicine & Diabetes Center, Ismailia General Hospital & Senior Research scientist, Port-Said University,Port Said,Egypt.
 
Biography
Dr. Hassan Shora is a senior researcher at Port-Said university, member of supervising committee of PhD&MSc theses in molecular medicine cooperating with staff of department of biochemistry&molecular biology at faculty of science.He also is the Head of medicine & Director of diabetes center at Ismailia General Hospital and works as a senior lecturer, Egyptian Board of physicians to train medical residents in Ismailia,Egypt. Dr. Shora is awarded Physician Recognition Award of The American Medical Association in 2003 and 2007. He published his first paper in 1984 while he was a second year undergraduate student and published several original research papers thereafter in international journals in role of adiponectin and glycemic control in delaying sub-clinical atherosclerotic changes in type 1 diabetics, markers of subclinical atherosclerosis in type 1 diabetics, visceral fat and liver size as determinants of subclinical athrosclerosis in type 1 diabetic adolescents, inflammatory bio-markers of cardio-metabolic risk in obese type 2 diabetics iron binding stores in correlation with cardio-metabolic risk in obese type 2 diabetics and NT ProPNB as a marker of micro-vascular complications in type 2 diabetes. Dr.Shora is a member of Asian Council of Science Editors and Editor of SMjournal of general medicine, Current Trends in General Practice and is working as editorial board member and peer reviewer for many journals. Dr. Shora researches interest in molecular diabetic medicine for novel bio markers to detect early complications of diabetes. Interests: Adiponectin, adipose tissue, obesity, atherosclerosis, diabetic micro vascular complications, cardio metabolic risk, novel anti-inflammatory therapies MoAb, for CVD prevention.
 
Research Interest
Adiponectin, adipose tissue, obesity, atherosclerosis, diabetic micro vascular complications, cardio metabolic risk, novel anti-inflammatory therapies MoAb, CVD prevention